KRAS and pancreatic ductal adenocarcinoma: Previous studies have suggested that the vast majority of pancreatic ductal adenocarcinoma (PDAC) harbor mutations in the KRAS gene, with cfDNA mutant KRAS being an early marker of disease recurrence [9,10].